These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1209 related articles for article (PubMed ID: 3665201)
1. Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells. Welt S; Carswell EA; Vogel CW; Oettgen HF; Old LJ Clin Immunol Immunopathol; 1987 Nov; 45(2):214-29. PubMed ID: 3665201 [TBL] [Abstract][Full Text] [Related]
2. Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity. Chapman PB; Lonberg M; Houghton AN Cancer Res; 1990 Mar; 50(5):1503-9. PubMed ID: 2105840 [TBL] [Abstract][Full Text] [Related]
3. Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. Cheresh DA; Honsik CJ; Staffileno LK; Jung G; Reisfeld RA Proc Natl Acad Sci U S A; 1985 Aug; 82(15):5155-9. PubMed ID: 3860849 [TBL] [Abstract][Full Text] [Related]
4. The idiotype (Id) cascade in mice elicited the production of anti-R24 Id and anti-anti-Id monoclonal antibodies with antitumor and protective activity against human melanoma. Ramos AS; Parise CB; Travassos LR; Han SW; de Campos-Lima PO; de Moraes JZ Cancer Sci; 2011 Jan; 102(1):64-70. PubMed ID: 21070480 [TBL] [Abstract][Full Text] [Related]
5. Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody. Chapman PB; Gillies SD; Houghton AN; Reilly RM Cancer Immunol Immunother; 1994 Sep; 39(3):198-204. PubMed ID: 7522964 [TBL] [Abstract][Full Text] [Related]
6. Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma. Bajorin DF; Chapman PB; Wong GY; Cody BV; Cordon-Cardo C; Dantes L; Templeton MA; Scheinberg D; Oettgen HF; Houghton AN Melanoma Res; 1992 Dec; 2(5-6):355-62. PubMed ID: 1292783 [TBL] [Abstract][Full Text] [Related]
7. Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside. Nasi ML; Meyers M; Livingston PO; Houghton AN; Chapman PB Melanoma Res; 1997 Aug; 7 Suppl 2():S155-62. PubMed ID: 9578432 [TBL] [Abstract][Full Text] [Related]
8. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Houghton AN; Mintzer D; Cordon-Cardo C; Welt S; Fliegel B; Vadhan S; Carswell E; Melamed MR; Oettgen HF; Old LJ Proc Natl Acad Sci U S A; 1985 Feb; 82(4):1242-6. PubMed ID: 3883355 [TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3. Ohta S; Honda A; Tokutake Y; Yoshida H; Hanai N Cancer Immunol Immunother; 1993; 36(4):260-6. PubMed ID: 8439988 [TBL] [Abstract][Full Text] [Related]
10. Melanoma antibodies: specificity and interaction with melanoma and cytotoxic T-cells. Dippold WG; Knuth A; Meyer zum Büschenfelde KH Behring Inst Mitt; 1984 May; (74):14-8. PubMed ID: 6332614 [TBL] [Abstract][Full Text] [Related]
11. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. Real FX; Houghton AN; Albino AP; Cordon-Cardo C; Melamed MR; Oettgen HF; Old LJ Cancer Res; 1985 Sep; 45(9):4401-11. PubMed ID: 4028024 [TBL] [Abstract][Full Text] [Related]
12. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. Vadhan-Raj S; Cordon-Cardo C; Carswell E; Mintzer D; Dantis L; Duteau C; Templeton MA; Oettgen HF; Old LJ; Houghton AN J Clin Oncol; 1988 Oct; 6(10):1636-48. PubMed ID: 3171629 [TBL] [Abstract][Full Text] [Related]
13. Recombinant antibodies against ganglioside expressed on tumor cells. Hanai N; Nakamura K; Shitara K Cancer Chemother Pharmacol; 2000; 46 Suppl():S13-7. PubMed ID: 10950141 [TBL] [Abstract][Full Text] [Related]
14. The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine. Milner RJ; Salute M; Crawford C; Abbot JR; Farese J Vet Immunol Immunopathol; 2006 Dec; 114(3-4):273-84. PubMed ID: 17027091 [TBL] [Abstract][Full Text] [Related]
15. Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside. Hellström I; Brankovan V; Hellström KE Proc Natl Acad Sci U S A; 1985 Mar; 82(5):1499-502. PubMed ID: 3856277 [TBL] [Abstract][Full Text] [Related]
16. GD3 ganglioside antibody augments tumoricidal capacity of canine blood mononuclear cells by induction of interleukin 12. Helfand SC; Dickerson EB; Munson KL; Padilla ML Cancer Res; 1999 Jul; 59(13):3119-27. PubMed ID: 10397254 [TBL] [Abstract][Full Text] [Related]
17. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro. Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994 [TBL] [Abstract][Full Text] [Related]
18. A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma. Minasian LM; Yao TJ; Steffens TA; Scheinberg DA; Williams L; Riedel E; Houghton AN; Chapman PB Cancer; 1995 May; 75(9):2251-7. PubMed ID: 7536122 [TBL] [Abstract][Full Text] [Related]
19. Anti-GD3 monoclonal antibody analysis of childhood T-cell acute lymphoblastic leukemia: detection of a target antigen for antibody-mediated cytolysis. Reaman GH; Taylor BJ; Merritt WD Cancer Res; 1990 Jan; 50(1):202-5. PubMed ID: 2403416 [TBL] [Abstract][Full Text] [Related]